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BACKGROUND 
This Project has been carried out within the Metabolomics Platform. The 
Metabolomics Platform is a joint research facility created in 2008 by URV (Universitat 
Rovira i Virgili) and CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes 
y Enfermedades Metabólicas Asociadas). The main goal of the Metabolomics Platform 
is to offer metabolomic services to the biomedical and clinical research groups from 
CIBERDEM and URV. This project is part of an on going internal CIBERDEM project in 
colaboration with Dra. Lourdes Ibañez from Hospital Sant Joan de Déu (Barcelona).  
 
PRESENTATION 
I started my phD in Metabolomics Platform in 2009. In my thesis, I have 
participated in several metabolomics experiments involving different analytical 
platforms (NMR, LC-MS and GC-MS). The project here described have been the last 
work presented in my doctoral thesis. I have contributed intensively in this work, 
technically and scientifically.  
In this project, I have developed an untargeted metabolomic workflow from 
sample preparation, data processing for metabolite identification (including statistical 
analysis) to biological interpretation. I have been involved in all of this steps. The main 
goal of this project was to implement a multiplatform approach based NMR and LC/MS 
to provide new insights in disease in a cohort of young lean hyperinsulinaemic 
androgen excess patients (For more details see ARTICLE). 
Untargeted metabolomics have the aim to simultaneously measure as many 
metabolites as possible from biological samples without bias. This metabolomic 
approach is typically hypothesis generating and provides a global comparative 
overview of metabolites abundances between two or more sample groups (i.e., 
experimental conditions), for example, healthy vs. disease or, WT (wild type) vs. KO 
(knock-out). The main bottleneck of an untargeted approach is the identification of 
metabolites on the basis of MS and/or NMR peaks from exceedingly complex datasets. 
Despite this challenge, this approach has the potential to involve previously 
unrecognized metabolites in seemingly known human pathological conditions. For this 
reason, this project has been focused on an untargeted metabolomic approach.  
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MY CONTRIBUTION 
The aim of this project was to determine the underlying mechanism by which 
hyperinsulinemic androgen exces is associated with long-term health risks in 
adulthood such as anovulatory infertility and long-term health risks such as type 2 
diabetes, metabolic syndrome and possibly cardiovascular disease. In this project we 
have been used NMR and MS-based metabolomics to compare the lipoprotein profile 
and the serum metabolome of non-obese adolescents with HIAE, with those in age- 
and weight-matched control girls. 
I have contributed to the experimental design; NMR, LC-MS and MALDI-TOF MS 
sample preparation; LC-MS data adquisition;  NMR, LC-MS and MALDI-TOF MS data 
analysis; biological interpretation and integration of all results. Moreover, I have 
written the whole final manuscript, excluding NMR and MADLI-TOF MS technical 
methods which were written by other authors. The entire study was supervised by 
Oscar Yanes.  The final manuscript was supervised by Oscar Yanes and Lourdes Ibañez.  
 
UNTARGETED METABOLOMICS EXPERIMENT 
In general, in untargeted metabolomic studies, numerous factors must be carefully 
considered. These factors include: sample preparation, implementation of appropriate 
MS and NMR analytical tools for sample analysis, data analysis, and last but not least, 
biological interpretation. Hence, a well-defined workflow characterizes untargeted 
metabolomics. All of this sections have been performed in this project. Sample 
preparation have been described in detail in (ARTICLE: MATERIALS AND METHODS). 
However, I have considered to expand the data analysis of this project. Once, data has 
adquired for LC-MS the first step is to convert the raw data into a standard format such 
as mzData using ProteoWizard. Then, a package based on R (xcms) has been used for 
data processing. The XCMS package provide methods for peak picking, non-linear 
retention time alignment, visualization, and relative quantitation. XCMS is 
implemented as a package within the R programming environment. XCMS implements 
three main steps: 
1. Peak detection: the algorithm identifies peaks in each of the samples; 
2. Non-linear retention time alignment: matches peaks with similar retention times 
across multiple samples, and use the groups of matched peaks for time alignment; 
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3. Fill in any missing peaks: the peaks that have failed to be detected in step 1, are 
filled in properly from raw data. 
As a result, the output matrix of XCMS includes the intensity under the peak for all 
features detected, for every sample. In this process, thousands of so called metabolite 
features are routinely generated. A feature is defined as a peak corresponding to an 
individual ion with a unique mass-to-charge ratio and a unique retention time. It is 
worth emphasizing that one feature is not equivalent to one metabolite. Generally, 
more than one feature belongs to the same metabolite. In LC-MS data, isotopic 
distributions, potential adducts or in-source fragmentation generates more than one 
feature for the same metabolite. Next, the statistical analysis will reveal which features 
are significantly different between sample groups. Finally, the last step is metabolite 
identification.  
Identification of metabolites by LC-MS:  
To determine the identity of a feature of interest, the accurate mass of the 
compound is first searched in metabolite databases such as Metlin or the Human 
Metabolome Database (HMDB).  
In this project, more than 50000 features were obtained after xcms processing 
from samples analyzed by LC-MS using HILIC chromatography. All of this features were 
filtered following different criterias (see the script section) and after filtering for 
statistical analysis (Yuen-Welch’s test) and fold change, I obtained 250 features that 
were statistically significant between control and disease. This 250 features were 
searched in Metlin database and only 80 of the initial 250 features returned a hit in the 
database. However, a database match represents only a putative assignment that must 
be confirmed by comparing the retention time and MS/MS data of a model compound 
to that from the feature of interest in the research sample. Currently, MS/MS data for 
features selected from the profiling results are obtained from additional experiments 
and matching of MS/MS fragmentation patterns is performed manually by inspection. 
Then, after running samples again with the aim to perform the MS/MS fragmentation 
experiments only  11 metabolites were identified.  
SCRIPT  
XCMS package: 
library(xcms) 
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# Perform peak detection on data in centroid mode using centWave 
algorithm 
xset<-xcmsSet(method="centWave",ppm=30,peakwidth=c(10,60)) 
# Match peaks across samples: place in to groups peaks representing 
the same metabolite #across samples 
xset<-group(xset) 
# Make use of group information to identify and correct retention time 
missalignments from run #to run using Obi-warp 
xset2<-retcor(xset,method="obiwarp",profStep=1) 
#Make a second pass of grouping algorithm to a more accurate group 
definition 
xset2<-group(xset2, mzwid=0.025,minfrac=0.5,bw =5) 
#Finally fill in missing peaks 
xset3<-fillPeaks(xset2) 
 
DATA PROCESSING (Filtering data) 
###Intensity criteria  
The accuracy of a metabolite identi_cation depends on the detection of all, most, or informative 
fragment ions generated during the MS/MS experiments. Lower-intensity parent ions obtained 
in profling mode lead to poor MS/MS spectra quality hampering this way a proper identi_cation. 
Therefore, it is worth to perform MS/MS experiments for those parent ions presenting a 
minimum intensity threshold. This threshold depends on the experimental conditions. However, 
according to our experience, a reasonable threshold in our example would be 10000 counts. 
 
# Get intensities from xcmsSet object 
X1 <- groupval(xset3, value = "maxo") 
# Define experimental groups 
class <- as.factor(xset3@phenoData$class) 
# Compute the mean intensities for each group 
meanintensities <- apply(X1, 1, function(x) tapply(x, class, mean)) 
# Getting index of those features with mean intensity above 10000 
counts in at least one of the #groups 
idx_intensity <- which(apply(meanintensities, 2, function(x) any(x 
>10000)) == TRUE) 
 
###Handle analytical variation: 
Most common sources of analytical variation in LC-MS experiments are due to sample 
preparation and instrumental drifts caused by chromatographic columns and MS detectors. The 
ideal method to examine analytical variation is to analyze quality control (QC) samples, which 
will provide robust quality assurance of each detected mzRT feature. To this end, QC samples 
should be prepared by pooling aliquots of each individual sample entering the study and 
analyze them periodically through-out the sample work list. 
 
Being replicates of the same pooled samples QC samples are expected to not contain biological 
variation. Hence variation observed in QC samples reects analytical variation. the performance 
of the analytical platform can be calculated individually for each detected mzRT feature 
computing the variation of each mzRT feature around their mean in QC pooled samples (CVQC). 
 
This leads to an estimation of the analytical variation. Additionally, we can also calculate the 
variation of mzRT features around their mean in the samples entering the experiment (CVS). 
This variation would enclose both, analytical and biological variation. 
 
Consequently, those mzRT features where CVQC > CVS contain more analytical variation than 
other sources of variation and they should be conveniently removed from further analysis. This 
criteria helps to focus on mzRT features holding the lowest proportion of analytical variation 
 
# 1-. Define (CV) function 
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co.var <- function(x) (100 * sd(x)/mean(x)) 
# 2-. Define QC and Sample samples classes 
cl1 <- rep(c("Sample", "QC"), times = c(38, 8)) 
# 3-. Compute CV for QC and Samples 
CV <- t(apply(X1, 1, function(x) tapply(x, cl1, co.var))) 
# 4-. Determine the percenteage of features where CV(Samples)>CV(QC) 
idx_qc <- which(CV[, "Sample"] > CV[, "QC"]) 
 
###Combine both criteria  
 
Combine both QC and Intensity criteria, filter the original dataset accordingly and get rid out 
of QC samples. 
 
# Combine both intensity and QC criteria 
Ii <- colnames(D)[idx_intensity] 
Iqc <- colnames(D)[idx_qc] 
Ib <- intersect(Ii, Iqc) 
# Create a new dataset without QC samples and with mZRT features 
meeting both criteria 
D2 <- subset(D, class != "QC", select = Ib) 
 
###Statistical analysis  
 
Provided the limitation in the number of MS/MS con_rmation experiments, additional criteria to 
those described above are necessary to further reduce the number of initial mzRT features to 
an amenable number. In our pipeline once QC and intensity criteria has been applied, the 
resulting dataset is usually specified via hypothesis testing to select mzRT features showing 
statistical signifcance. 
 
# Yuen function 
 
library(PairedData) 
 
Yuen_sara<-function (x,y) 
{ 
  resultyuen<-list(1:ncol(x)) 
  pvalue<-matrix(nrow=ncol(x),ncol=1) 
  colnames(pvalue)<-"pvalue" 
  rownames(pvalue)<-colnames(x) 
 
  for (i in 1:ncol(x)){ 
 
    resultyuen[[i]]<-yuen.t.test(x[,i],y[,i], tr=0.2, paired=FALSE) 
    pvalue[i,1]<-resultyuen[[i]]$p.value 
 
  } 
  return(pvalue) 
} 
 
##Create two matrices 
 
CTR<-D2[1:14,] 
PCOS<-D2[15:26,] 
 
pvalue_ctr_pcos <- Yuen_sara(CTR,PCOS) 
 
 
#Create the fold change function 
fc.test<-function(D2,classvector){ 
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means<-apply(D2, 2, function(x) tapply(x, classvector, mean)) 
means <- t(means) 
case <- means[,"case"];control <- means[,"control"] 
logFC <- log2(case/control) 
FC <- case/control; 
FC2 <- -control/case 
FC[FC<1] <- FC2[FC<1] 
fc.res <- cbind(FC, logFC) 
return(fc.res) 
} 
 
# Create a new group factor that does not include QC samples 
gr <- as.factor(xset3@phenoData$class[xset3@phenoData$class != "QC"]) 
 
#Calculate FC for "DISEASE-CTR" groups 
#Define control/case groups 
gr2 <- as.character(gr) 
gr2[gr2=="CTR"] <- "control" 
gr2[gr2=="DISEASE"] <- "case" 
#Calculate FC using fc.test function 
fc.res <- fc.test(D2,gr2) 
D3<- data.frame(pvalue_ctr_pcos, fc.res) 
 
#Find those mzRT features matching statistical and fold change 
criteria 
D3$threshold = as.factor(abs(D3$FC) > 1.5 & D3$pvalue.ctr_pcos < 
0.01); 
 
#Calculate the number of features that match this criteria 
table(D3$threshold)["TRUE"] 
## TRUE 
## 250 
 
#Select those features 
idxD3red <- rownames(D3)[which(D3$threshold == "TRUE")] 
D3red <- D3[idxD3red,] 
 
 
#Putative identification 
 
Once initial xcmSet has been properly filtered, a good way to organize the resulting dataset is to 
rank significantly varied mZRT features according to their FC value. The final result would be a 
list of relevant features and their corresponding exact mass to query them to databases. From 
the initially filtered mZRT features, just those matching exact mass to database are retained for 
further MS/MS monitoring. It is important to collect all necessary information for these MS/MS 
spectra adcquisition. 
 
Retention time, exact mass, and group mean intensities are mandatory.Another important poind 
is to visually inspect these relevant mZRT features. Although XCMS have some functionalities 
to display diferential data, it does not allow an iterative environment to explore it. Functions in 
XCMS to visualize data require to go back to mzXML files. Therefore, we should always operate 
in the directory where mzXML data is located. At this point, vendor software might offer better 
capabilities for displaying purposes and more exibility to visually inspect main results. 
 
 
For NMR, raw data are typically processed by means of Fourier Transform (FT) and 
baseline removal. Baseline distortions affect not only the statistical analysis but also 
the quantification of metabolites. Multi integration of Regions of Interest (ROIs) is the 
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method used in this project. In this approach, the analysis is not directly based on 
peaks or spectal binned regions but on regions which are a priori known to contain 
compound resonances or ROIs. The area under ROIs representative of metabolites can 
be considered as a surrogate of the relative abundance of these metabolites in the the 
biological sample. The key issue here is to properly assign ROIs resonances to 
metabolite structures. This is not a trivial issue. NMR peak structure assignemnt in 
complex data matrices such as in cell cultures requires a skilled NMR specialist, 
acquisition of 2D NMR spectra and libraries of pure compounds to compare with. This 
assignment is actually the bottle neck in the whole NMR-based metabolic analysis. 
Noteworthy, it is eventually impossible to assign all resonances arising from complex 
matrices to chemical structures. Therefore, we will much probably end-up with some 
unknown resonances. Despite this daughting scenario, in this project, I have used a 
commercial software, AMIX, which incorporate libraries of pure standar compounds 
resulting in great help for the resonance assignment process.  
 
Analyzing Multi Integration Results 
# Yuen function 
 
library(PairedData) 
 
Yuen_sara<-function (x,y) 
{ 
  resultyuen<-list(1:ncol(x)) 
  pvalue<-matrix(nrow=ncol(x),ncol=1) 
  colnames(pvalue)<-"pvalue" 
  rownames(pvalue)<-colnames(x) 
 
  for (i in 1:ncol(x)){ 
 
    resultyuen[[i]]<-yuen.t.test(x[,i],y[,i], tr=0.2, paired=FALSE) 
    pvalue[i,1]<-resultyuen[[i]]$p.value 
 
  } 
  return(pvalue) 
} 
 
##Create two matrices 
 
data<-read.table("multiintegration.txt",sep="\t", header=T) 
CTR<-data[1:14,] 
PCOS<-data[15:26,] 
 
##Apply the function 
 
pvalue_ctr_pcos <- Yuen_sara(CTR,PCOS) 
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Lipoprotein profile and biochemical parameters 
The technical issues of this parameters have been performed for other colleges which 
have contributed  in the elaboration of this article. However, the statistical analysis of 
all of them and the figures and tables in the paper related to this issues have been 
performed by me. Statistical analysis have been performed in R.  
SCRIPT 
data1 <- read.table("Bioquimica_ctr_pcos_pio.txt", header=T, sep="\t") 
data2<- read.table("Lipos_roger.txt", header=T, sep="\t") 
data <- data1 [,2:13] 
rownames(data) <- data1[,1] 
lipos <- data2 [,2:13] 
rownames(lipos) <- data2[,1] 
rm(data1,data2) 
##divido la matriz 
CTR <- data[1:14,] 
PCOS <- data[15:26,] 
PIO <- data[27:32,] 
##LIPOS 
CTRL <- lipos[1:14,] 
PCOSL <- lipos[15:26,] 
PIOL <- lipos[27:32,] 
 
##yuen test 
Yuen_sara<-function (x,y) 
{ 
  resultyuen<-list(1:ncol(x)) 
  pvalue<-matrix(nrow=ncol(x),ncol=1) 
  colnames(pvalue)<-"pvalue" 
  rownames(pvalue)<-colnames(x) 
    for (i in 1:ncol(x)){ 
        resultyuen[[i]]<-yuen.t.test(x[,i],y[,i], tr=0.2, 
paired=FALSE) 
    pvalue[i,1]<-resultyuen[[i]]$p.value 
      } 
  return(pvalue) 
} 
library(PairedData) 
pvalue_ctr_pcos <- Yuen_sara(CTR,PCOS) 
pvalue_ctr_pio <- Yuen_sara(CTR,PIO) 
pvalue_pcos_pio <- Yuen_sara(PCOS,PIO) 
pvalue_ctr_pcos_LIPOS <- Yuen_sara(CTRL,PCOSL) 
pvalue_ctr_LIPOS <- Yuen_sara(CTRL,PIOL) 
pvalue_pcos_LIPOS <- Yuen_sara(PCOSL,PIOL) 
 
Once, all data have been generated, biological interpretation have to be performed. 
The use of Cytoscape software for metabolic pathway analysis and searches in the 
literature were performed exhaustively by me.  
I found that 9 metabolites found in the untargeted metabolomic experiment belong to the same 
pathway, in concrete to the gamma glutamyl cycle. The gamma-glutamyl cycle plays a key role 
in the synthesis and degradation of GSH. Most metabolites are increased in hyperinsulinemic 
androgen excess women which I associated with an increased demand of GSH due to 
increased oxidative stress (which has been extensively described in the literature). However 
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methionine and methionine sulfoxide were not involved in this pathway. Interestingly, lower 
levels of methionine in serum samples of hyperinsulinemic androgen excess women were 
associated with greater levels of methionine sulfoxide in these patients, indicating increased 
oxidation of this aminoacid. By other hand, I found a paper publish in 2008 demonstrates that 
methionine oxidation in apo-AI impairs reverse cholesterol transport by LCAT. Specifically 
oxidation of Met-148 residue in apo-AI  changes the 3D structure of the protein imparing the 
activity of LCAT in HDL lipoproteins affecting the maturation of nascent HDL particles. In 
addition, I observe a very good correlation between large HDL and methionine sulfoxide levels. 
Increased concentration of methionine sulfuxide in serum of PCOS is associated with lower 
levels of large HDL particles.  Therfore, I hypothetized that women with hyperinsulinemia 
androgen excess present greater oxidation of methionine residues in apo-AI relative to healthy 
women, and the increased levels of free methionine sulfoxide in hyperinsulinemic androgen 
excess patients may result from the turnover and degradation of these apo-AI proteins. With the 
aim to verify this hypothesis I proposed to perform a quantitative analysis of oxidized 
methionine/methionine ratio in apo AI. After protein precipitation serum samples were separed 
by SDS electrophoresis, and ApoA1 gel bands were digested and measured by MALDI-TOF 
MS (See results in appendice). 
 
All plots performed in this project have been done by me. I have used ggplot2 library. 
Scripts code: 
 
FIGURE 1: 
 
####PASAR EL PLOT DE ROGER DE MATLAB A R#### 
 
setwd("C:/Documents and Settings/Sara/Escritorio/Ibañez_02/Final 
Data/Julio2014/Figures/LIPOS ROGER/R") 
 
methyl <- read.table("Total_metyl.txt", header=TRUE, sep="\t") 
 
library(ggplot2) 
 
cols <- c("Experimental Spectra"="black", "Fitted Spectra"="red", 
"Background"="grey", "VLDL"="#E69F00","Large LDL"= "#56B4E9", "Small 
LDL"="#009E73", "Large HDL"="#F0E442", "Medium HDL"="#0072B2", "Small 
HDL"="#D55E00") 
 
m <- ggplot(methyl, aes(x=x.axis, y=Total.line)) + 
geom_line(aes(x=x.axis, y=Total.line, colour="Experimental Spectra"), 
size=1) + xlim(1,0.7) 
 
m <- m + geom_line(aes(x=x.axis, y=Total.subfractions, colour="Fitted 
Spectra"), size=1) 
 
m <- m + xlab("ppm") 
 
m <- m + theme(axis.title.x= element_text(color="#999999", 
face="bold",size=16)) 
 
m <- m + ylab("Intensity") 
 
m <- m + theme(axis.title.y= element_text(color="#999999", 
face="bold",size=16)) 
 
m <- m + geom_line(aes(x=x.axis, y=Background, colour="Background"), 
size=0.5 ) 
 
m <- m + geom_line(aes(x=x.axis, y=VLDL, colour="VLDL"), size=1) 
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m <- m + geom_line(aes(x=x.axis, y=large.LDL, colour="Large LDL"), 
size=1) 
 
m <- m + geom_line(aes(x=x.axis, y=small.LDL, colour="Small LDL"), 
size=1) 
 
m <- m + geom_line(aes(x=x.axis, y=large.HDL, colour="Large HDL"), 
size=1) 
 
m <- m + geom_line(aes(x=x.axis, y=medium.HDL, colour="Medium HDL"), 
size=1) 
 
m <- m + geom_line(aes(x=x.axis, y=small.HDL, colour="Small HDL"), 
size=1) 
 
m <- m + scale_colour_manual( values = c("Experimental 
Spectra"="black", "Fitted Spectra"="red", "Background"="grey", 
"VLDL"="#E69F00","Large LDL"= "#56B4E9", "Small LDL"="#009E73", "Large 
HDL"="#F0E442", "Medium HDL"="#0072B2", "Small HDL"="#D55E00"), 
breaks=c("Experimental Spectra", "Fitted Spectra", "Background", 
"VLDL","Large LDL", "Small LDL", "Large HDL", "Medium HDL", "Small 
HDL")) 
 
m <- m + ggtitle("Lipoprotein Deconvolution") + theme(plot.title = 
element_text(size=18)) 
 
m 
 
FIGURE 2 and FIGURE 3: 
 
###PARA PINTAR LOS PLOTS INDIVIDUALES DE CADA VARIABLES 
 
##tengo mi matriz data, quiero que sea un data.frame y que incorpore 
#dos columnas, una con un factor que me defina las clases y otra 
#con un vector que me defina los grupos(para que me pinte por colores) 
 
colores <- rep(c("CTR","PCOS","PIOFLUMET"), times=c(14,12,6)) 
class <- as.factor(colores) 
data <- as.data.frame(data) 
 
###defino un dataframe al que le añado las dos columnas con las 
variables 
##creadas 
 
pintar <-cbind(class,colores,data) 
 
##quiero pintar para todos los metabolitos primero solo de CTR vs PCOS 
 
metabolites <- c("Methionine","Methionine Sulfoxide", "5-
oxoproline","Taurine", "Glu-Cys", "Glu-Glu", "Glutamate", "GSH", 
"GSH/GSSG", "Glu-Taurine", "Glycine") 
 
ctrvspcos <- pintar[1:26,] 
 
library(ggplot2) 
 
###Para los gráficos del gamma-glutamyl cycle 
 
ylabel <- rep(c("Intensity","Arbitrary Units"), times=c(10,1)) 
metabolites <- colnames(pintar) 
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cont <- 1 
 
 
for (i in 12:22) { 
 
  name<-paste(metabolites[i],".svg") 
 
  pintar1 <- ctrvspcos[,1:2] 
  pintar1 <- cbind(pintar1, ctrvspcos[,i]) 
  #colnames(pintar1)[3] <- colnames(pintar)[i] 
  #metabolite <- colnames(pintar1)[3] 
 
  b <- ggplot(pintar1, aes(x=class, y = log10(ctrvspcos[,i]), color = 
colores)) + geom_point(size = 4, position = position_jitter(w = 0.1)) 
 
  b <- b + geom_segment(x=0.75, 
y=mean(log10(pintar1[1:14,3]),trim=0.2), xend=1.25, 
yend=mean(log10(pintar1[1:14,3]),trim=0.2, colour="black"), size=1, 
colour="black") 
 
  b <- b <- b + geom_segment(x=1.75, 
y=mean(log10(pintar1[15:26,3]),trim=0.2), xend=2.25, 
yend=mean(log10(pintar1[15:26,3]),trim=0.2, colour="black"), size=1, 
colour="black") 
 
  #b <-  b + geom_segment(x=2.75, y=mean(pintar1[27:32,3],trim=0.2), 
xend=3.25, yend=mean(pintar1[27:32,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
  b <- b + ggtitle(label.title[i]) + theme(plot.title = 
element_text(size=18, face="bold")) 
 
  b <- b + theme(axis.title.x = element_blank()) + 
ylab(paste("log10(",ylabel[cont], ")")) 
 
  b <- b + theme(axis.text.x  = element_text(size=16)) + 
theme(axis.text.x= element_text(face="bold")) 
 
  b <- b + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(face="bold")) 
 
  b <- b + theme(legend.position="none") 
 
  b <- b + coord_fixed(ratio=3/0.75) 
 
  b 
  ggsave(name, dpi=300) 
  cont <- cont+1 
} 
 
FIGURE 4: 
 
####plots de proteomica 
 
setwd("X:/YANES LAB/USUARIS 
(YanesLab)/Sara/Plataforma/Usuaris/Ibañez_02/Final 
Data/Julio2014/Figures/Proteomica_Lipos") 
 
pintar <- DATA[1:18,] 
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colores <- rep(c("CTR","HIAE","PIOFLUMET"), times=c(8,10,5)) 
class <- as.factor(colores) 
col <- rep(c("#F8766D", "#619CFF", "#00BA38"), times=c(8,10,5)) 
 
pintar <- cbind(class,colores,col, DATA) 
 
ctrvspcos <- pintar[1:18,] 
 
library(ggplot2) 
 
###para el gráfico de la Met-148 
 
name<-paste("Met-148",".svg") 
 
pintar1 <- ctrvspcos[,1:4] 
pintar1 <- pintar1[,-3] 
 
b <- ggplot(pintar1, aes(x=class, y = ctrvspcos[,4], color = colores)) 
+ geom_point(size =4, position = position_jitter(w = 0.1), 
colour=col1) 
 
b <- b + geom_segment(x=0.75, y=mean(pintar1[1:8,3],trim=0.2), 
xend=1.25, yend=mean(pintar1[1:8,3],trim=0.2), colour="black", size=1, 
colour="black") 
 
b <- b <- b + geom_segment(x=1.75, y=mean(pintar1[9:18,3],trim=0.2), 
xend=2.25, yend=mean(pintar1[9:18,3],trim=0.2), colour="black",size=1, 
colour="black") 
 
#b <-  b + geom_segment(x=2.75, y=mean(pintar1[27:32,3],trim=0.2), 
xend=3.25, yend=mean(pintar1[27:32,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <- b + ggtitle("MetOx-148/Met-148") + theme(plot.title = 
element_text(size=18)) 
 
b <- b + theme(axis.title.x = element_blank()) + ylab("Ratio MetOx-
148/Met-148 in ApoAI") 
 
b <- b + theme(axis.text.x  = element_text(size=16, color="#999999")) 
+ theme(axis.text.x= element_text(face="bold")) 
 
b <- b + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(color="#999999", face="bold")) 
 
b <- b + theme(legend.position="none") 
 
b <- b + coord_fixed(ratio=2/2) 
 
b 
ggsave(name, dpi=300) 
 
 
###ahora vamos a hacer scatter plot de metox vs meth sufloxide in 
serum 
###creamos el dataframe 
 
pintar1 <- pintar[,c(4,6)] 
ctrvspcos <- pintar1[1:18,] 
 
###modelo lineal 
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source("C:/ScriptsR/Functions R/pbcor.r") 
source("C:/ScriptsR/Functions R/pbos.r") 
library(MASS) 
 
model <- pbcor(ctrvspcos[,2],ctrvspcos[,1], beta=0.2) 
robust <-rlm(Ratio.Met.148~Methionine.Sulfoxide, data=ctrvspcos) 
 
p <- ggplot(ctrvspcos, aes(x=Methionine.Sulfoxide, y=Ratio.Met.148, 
color=colores[1:18])) + geom_point(shape=19, size=4, colour=col[1:18]) 
 
p <- p + geom_abline(intercept = robust[[1]][1], slope = 
robust[[1]][2], colour="black", size=1) 
 
p <- p + ylab("Ratio MetOx-148/Met-148 in ApoAI") + theme(axis.title.y  
= element_text(size=16)) + theme(axis.title.y= 
element_text(color="#999999", face="bold")) 
 
p <- p + xlab("Methionine Sulfoxide in Serum \n (Intensity Value)") + 
theme(axis.title.x  = element_text(size=16)) + theme(axis.title.x= 
element_text(color="#999999", face="bold")) 
 
p <- p +  theme(axis.text.x= element_text("Intensity Value")) 
 
p 
 
name <- paste("correlation_metox_metsulfo",".svg") 
ggsave(name, dpi=300) 
 
 
###ahora vamos a hacer scatter plot de large HDL vs meth sufloxide in 
serum 
###creamos el dataframe 
 
pintar1 <- cbind(pintar[,2],pintar[,6], pintar[,19]) 
colnames(pintar1) <- c("colores", "Methionine.Sulfoxide", "Large.HDL") 
ctrvspcos <- pintar1[1:18,] 
ctrvspcos <- as.data.frame(ctrvspcos) 
ctrvspcos[,1] <- rep(c("CTR","HIAE"), times=c(8,10)) 
ctrvspcos[,1] <- as.factor(ctrvspcos[,1]) 
 
 
###modelo lineal 
 
source("C:/ScriptsR/Functions R/pbcor.r") 
source("C:/ScriptsR/Functions R/pbos.r") 
 
library(MASS) 
library(ggplot2) 
 
model <- pbcor(ctrvspcos[,2],ctrvspcos[,3], beta=0.2) 
robust <-rlm(Large.HDL~Methionine.Sulfoxide, data=ctrvspcos) 
 
p <- ggplot(ctrvspcos, aes(x=Methionine.Sulfoxide, y=Large.HDL, 
color=colores)) + geom_point(shape=19, size=4,colour=col[1:18]) 
 
p <- p + geom_abline(intercept = robust[[1]][1], slope = 
robust[[1]][2], colour="black", size=1) 
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p <- p + ylab("Large HDL \n (% Relative area)") + theme(axis.title.y  
= element_text(size=16)) + theme(axis.title.y= 
element_text(color="#999999", face="bold")) 
 
p <- p + xlab("Methionine Sulfoxide in Serum \n (Intensity Value)") + 
theme(axis.title.x  = element_text(size=16)) + theme(axis.title.x= 
element_text(color="#999999", face="bold")) 
 
p 
 
name <- paste("correlation_large_hdl_metsulfo",".svg") 
ggsave(name, dpi=300) 
 
FIGURE 5: 
 
###Plots del tratamiento 
 
setwd("X:/YANES LAB/USUARIS 
(YanesLab)/Sara/Plataforma/Usuaris/Ibañez_02/Final 
Data/Julio2014/Figures/Treatment") 
 
###funcion para saber los codigos de los colores por default de ggplot 
 
ggplotColours <- function(n=6, h=c(0, 360) +15){ 
  if ((diff(h)%%360) < 1) h[2] <- h[2] - 360/n 
  hcl(h = (seq(h[1], h[2], length = n)), c = 100, l = 65) 
} 
 
codigos <- ggplotColours(n=3) 
 
 
###voy a pintar la ratio de MetOx 
library(ggplot2) 
 
pintar1 <- pintar[,1:3] 
col <- rep(c("#F8766D", "#619CFF", "#00BA38"), times=c(8,10,5)) 
pintar1 <- cbind(pintar1,col) 
 
b <- ggplot(pintar1, aes(x=class, y = pintar1[,3], color = colores)) + 
geom_point(size = 4, position = position_jitter(w = 0.1), colour=col) 
 
b <- b + geom_segment(x=0.75, y=mean(pintar1[1:8,3],trim=0.2), 
xend=1.25, yend=mean(pintar1[1:8,3],trim=0.2, colour="black"), size=1, 
colour="black") 
 
b <- b <- b + geom_segment(x=1.75, y=mean(pintar1[9:18,3],trim=0.2), 
xend=2.25, yend=mean(pintar1[9:18,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <-  b + geom_segment(x=2.75, y=mean(pintar1[19:23,3],trim=0.2), 
xend=3.25, yend=mean(pintar1[19:23,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <- b + ggtitle("MetOx-148/Met-148") + theme(plot.title = 
element_text(size=18)) 
 
b <- b + theme(axis.title.x = element_blank()) + ylab("Ratio MetOx-
148/Met-148 in ApoAI") 
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b <- b + theme(axis.text.x  = element_text(size=16, color="#999999")) 
+ theme(axis.text.x= element_text(face="bold")) 
 
b <- b + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(color="#999999", face="bold")) 
 
b <- b + theme(legend.position="none") 
 
b <- b + coord_fixed(ratio=2/2) 
 
b 
 
ggsave(paste("MetOx",".svg"), dpi=300) 
 
###hago el pca 
 
pca <- prcomp(DATA, scale=TRUE) 
class <- pintar1$class 
scores <- data.frame(pca$x[, 1:2], class,col) 
 
 
r <- ggplot(data = scores, aes(x = PC1, y = PC2, colour = colores)) + 
geom_point(size =6, colour=col) 
 
r <- r + geom_hline(aes(yintercept = 0), linetype="dashed") + 
geom_vline(aes(yintercept = 0), linetype="dashed") 
 
r <- r + xlab("PC1 (46.5%)") + ylab("PC2 (14.8%)") 
 
r <- r + theme(axis.title.x  = element_text(size=16, color="#999999")) 
+ theme(axis.title.x= element_text(face="bold")) 
 
r <- r + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(color="#999999", face="bold")) 
 
r 
 
ggsave(paste("PCA",".svg"), dpi=300) 
 
###LOADIGNS DEL PCA 
 
load <- pca$rotation[,1] 
loadings <- cbind(colnames(DATA),load) 
loadings <- as.data.frame(loadings) 
loadings <- cbind(loadings,load) 
loadings <- loadings[-2] 
 
 
loadings <- loadings[-1] 
 
ylabel <- c("Ratio Met-148","Methionine","Methionine Sulfoxide","5-
oxoproline","Taurine", 
            "Glu-Cys","Glu-Glu","Glutamate","GSH","GSH/GSSG","Glu-
Taurine","Glycine", 
            "VLDL","Large LDL","Small LDL","Large HDL", "Medium HDL", 
"Small HDL") 
 
loadings <- cbind(ylabel,loadings) 
colnames(loadings) <- c("metabolites","PC1") 
metab <- loadings$metabolites 
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l <- ggplot(loadings, aes(x=metabolites, y=PC1)) + 
geom_bar(data=subset(loadings, PC1>=0),stat="identity") + 
  geom_bar(data=subset(loadings, PC1<0),stat="identity") 
 
l <- l + coord_flip() 
 
l <- l + scale_x_discrete(limits=metab) 
 
l <- l + theme(axis.title.y = element_blank()) 
 
l 
 
ggsave(paste("loadings",".svg"), dpi=300) 
 
###para pintar methionine y methionine sulfoxide 
###tengo q cargar el dataset que esta en la carpeta de gamma 
glutamyl... 
 
colores <- rep(c("CTR","HIAE","PIOFLUMET"), times=c(14,12,6)) 
class <- as.factor(colores) 
col <- rep(c("#F8766D", "#619CFF", "#00BA38"), times=c(14,12,6)) 
 
pintar <- cbind(class,colores,col, data) 
library(ggplot2) 
 
pintar1 <- pintar[,1:2] 
pintar1 <- cbind(pintar1,pintar[,13]) ###Methionine 
colnames(pintar1[4]) <- "Methionine" 
 
###pinto 
 
b <- ggplot(pintar1, aes(x=class, y = log10(pintar1[,3]), color = 
colores)) + geom_point(size = 4, position = position_jitter(w = 0.1), 
colour=col) 
 
b <- b + geom_segment(x=0.75, y=mean(log10(pintar1[1:14,3]),trim=0.2), 
xend=1.25, yend=mean(log10(pintar1[1:14,3]),trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <- b <- b + geom_segment(x=1.75, 
y=mean(log10(pintar1[15:26,3]),trim=0.2), xend=2.25, 
yend=mean(log10(pintar1[15:26,3]),trim=0.2, colour="black"), size=1, 
colour="black") 
 
b <-  b + geom_segment(x=2.75, 
y=mean(log10(pintar1[27:32,3]),trim=0.2), xend=3.25, 
yend=mean(log10(pintar1[27:32,3]),trim=0.2, colour="black"), size=1, 
colour="black") 
 
b <- b + ggtitle("Methionine") + theme(plot.title = 
element_text(size=18)) 
 
b <- b + theme(axis.title.x = element_blank()) + 
ylab("log10(Intensity)") 
 
b <- b + theme(axis.text.x  = element_text(size=16, color="#999999")) 
+ theme(axis.text.x= element_text(face="bold")) 
 
b <- b + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(color="#999999", face="bold")) 
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b <- b + theme(legend.position="none") 
 
b <- b + coord_fixed(ratio=2/1.5) 
 
b 
 
ggsave(paste("Methionine",".svg"), dpi=300) 
 
###Methionine sulfoxide 
pintar1 <- pintar[,1:2] 
pintar1 <- cbind(pintar1,pintar[,14]) ###Methionine Sulfoxide 
colnames(pintar1[3]) <- "Methionine.Sulfoxide" 
 
###pinto 
 
b <- ggplot(pintar1, aes(x=class, y = log10(pintar1[,3]), color = 
colores)) + geom_point(size = 4, position = position_jitter(w = 0.1), 
colour=col) 
 
b <- b + geom_segment(x=0.75, y=mean(log10(pintar1[1:14,3]),trim=0.2), 
xend=1.25, yend=mean(log10(pintar1[1:14,3]),trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <- b <- b + geom_segment(x=1.75, 
y=mean(log10(pintar1[15:26,3]),trim=0.2), xend=2.25, 
yend=mean(log10(pintar1[15:26,3]),trim=0.2, colour="black"), size=1, 
colour="black") 
 
b <-  b + geom_segment(x=2.75, 
y=mean(log10(pintar1[27:32,3]),trim=0.2), xend=3.25, 
yend=mean(log10(pintar1[27:32,3]),trim=0.2, colour="black"), size=1, 
colour="black") 
 
b <- b + ggtitle("Methionine Sulfoxide") + theme(plot.title = 
element_text(size=18)) 
 
b <- b + theme(axis.title.x = element_blank()) + 
ylab("log10(Intensity)") 
 
b <- b + theme(axis.text.x  = element_text(size=16, color="#999999")) 
+ theme(axis.text.x= element_text(face="bold")) 
 
b <- b + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(color="#999999", face="bold")) 
 
b <- b + theme(legend.position="none") 
 
b <- b + coord_fixed(ratio=2/1.5) 
 
b 
 
ggsave(paste("MethionineSulfoxide",".svg"), dpi=300) 
 
 
###large HDL 
 
pintar1 <- pintar[,1:2] 
pintar1 <- cbind(pintar1,pintar[,10]) ###Large HDL 
colnames(pintar1[3]) <- "Large.HDL" 
###pinto 
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b <- ggplot(pintar1, aes(x=class, y = pintar1[,3], color = colores)) + 
geom_point(size = 4, position = position_jitter(w = 0.1), colour=col) 
 
b <- b + geom_segment(x=0.75, y=mean(pintar1[1:14,3],trim=0.2), 
xend=1.25, yend=mean(pintar1[1:14,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <- b <- b + geom_segment(x=1.75, y=mean(pintar1[15:26,3],trim=0.2), 
xend=2.25, yend=mean(pintar1[15:26,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <-  b + geom_segment(x=2.75, y=mean(pintar1[27:32,3],trim=0.2), 
xend=3.25, yend=mean(pintar1[27:32,3],trim=0.2, colour="black"), 
size=1, colour="black") 
 
b <- b + ggtitle("Large HDL") + theme(plot.title = 
element_text(size=18)) 
 
b <- b + theme(axis.title.x = element_blank()) + ylab("% Relative 
Area") 
 
b <- b + theme(axis.text.x  = element_text(size=16, color="#999999")) 
+ theme(axis.text.x= element_text(face="bold")) 
 
b <- b + theme(axis.title.y  = element_text(size=16)) + 
theme(axis.title.y= element_text(color="#999999", face="bold")) 
 
b <- b + theme(legend.position="none") 
 
 
b 
 
ggsave(paste("largeHDL",".svg"), dpi=300) 
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ABSTRACT 
Hyperinsulinaemic androgen excess (HIAE) is the phenotypic core for polycystic 
ovary syndrome (PCOS). HIAE in prepubertal and pubertal girls usually precedes a 
broader PCOS phenotype in adulthood that is associated with anovulatory infertility 
and long-term health risks such as type 2 diabetes (T2D), metabolic syndrome and 
possibly cardiovascular disease (CVD). With the aim of determining the underlying 
mechanism by which HIAE is associated with these long-term health risks in adulthood, 
here we use NMR and MS-based metabolomics to compare the lipoprotein profile and 
the serum metabolome of non-obese adolescents with HIAE, with those in age- and 
weight-matched control girls. We demonstrate that elevated levels of methionine 
sulfoxide in HIAE serum are strongly correlated with the degree of oxidation of 
methionine residues in apolipoprotein-A1. As a result, there is an impaired maturation 
of HDL reflected in a decline of large HDL particles in girls with HIAE. Remarkably, these 
metabolic disturbances were partially restored after 18 months of treatment with a 
combination of insulin sensitizers plus an anti-androgen (pioglitazone, metformin and 
flutamide). We postulate that hyperandrogenism and hyperinsulinemia are responsible 
for the oxidative damage in lipoproteins. Taken together, these metabolite changes 
might also constitute biomarkers of pre-diabetes and metabolic syndrome. 
 
INTRODUCTION 
Polycystic ovary syndrome (PCOS) is an evolving concept that, depending on the 
diagnostic criteria applied and population studied, affects 8-21% of women of 
reproductive age worldwide (Azziz et al., 2004; Franks, 1995; March et al., 2010). The 
phenotypic core of PCOS as we know it today, however, consists of women with 
hyperinsulinemic androgen excess (HIAE) (Barbieri RL et al., 1988; Chang RJ et al., 
1983; Dunaif, 1997; Ibanez et al., 2014). HIAE is a hallmark present in both obese and 
non-obese adolescent girls that continues into adult women with a PCOS-like 
phenotype (Apter D et al., 1995; Lewy VD et al., 2001). The mechanism by which HIAE 
is manifested at the early stages of a broader PCOS phenotype is currently under 
debate (Corbett S and Morin-Papunen L, 2013; de Zegher F and Ibáñez L, 2009; 
Tsilchorozidou et al., 2004). The “prenatal androgen excess” hypothesis (de Zegher F 
and Ibáñez L, 2009; Tsilchorozidou et al., 2004) appears to have been refuted in favour 
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of the “adipose tissue hypertrophy” hypothesis (de Zegher F et al., 2009; Ibanez et al., 
2014). The latter represents a mismatch between early adipogenesis and later fat 
mass, which establishes an individual setpoint determined by a wide range of 
environmental and genetic factors beyond which further lipid storage is rapidly 
accompanied by lipotoxicity and metabolic complications, including insulin resistance 
and androgen excess (Tsilchorozidou et al., 2004). Irrespective of whether 
hyperandrogenism results from the hyperinsulinaemia of insulin resistance, or vice 
versa, HIAE in prepubertal and pubertal girls precedes a broader PCOS phenotype in 
adulthood that is associated with anovulatory infertility and long-term health risks 
such as metabolic syndrome, type 2 diabetes, (Gambineri A et al., 2012) and possibly 
cardiovascular disease (Fauser BC, 2012; Talbott EO et al., 2000).  
Consequently, adolescence becomes a key period for the study of early biomarkers 
of long-term health risks, as well as for identifying symptomatic girls who might benefit 
from early therapeutic interventions, thereby decreasing subsequent metabolic 
abnormalities related to HIAE (Ibanez et al., 2014). In this regard, a low-dose 
combination of pioglitazone (an insulin-sensitizer), flutamide (an androgen-receptor 
blocker) and metformin (an insulin-sensitizer) has been found to normalize the 
endocrine-metabolic profile of adolescent girls with HIAE, as judged by markers of 
insulin sensitivity, visceral adiposity, arterial health, low-grade inflammation and 
menstrual regularity (Ibanez et al., 2011; Ibanez et al., 2010). This combination of 
insulin sensitizers plus an anti-androgen demonstrates the potential of therapeutic 
approaches based on a good knowledge of the pathological process of HIAE, in 
contrast to symptom-directed treatments –for example, with oral contraceptives- that 
seek at improving the clinical signs  (hirsutism and/or acne) and at inducing regular 
cycles yet persistently anovulatory (Dronavalli and Ehrmann, 2007; Kobaly et al., 2014; 
Legro RS, 2013).  
In this context, here we aimed at identifying as yet undefined metabolic alterations 
implicated in the early stages of the PCOS phenotype that may facilitate early 
intervention and thus potentially prevent later metabolic complications. 
To achieve this goal, we used mass spectrometry (MS) and nuclear magnetic 
resonance (NMR)-based metabolomics. Metabolomics enables the characterization of 
metabolites, the chemical entities that are transformed during metabolism and 
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provide a functional readout of cellular biochemistry (Patti et al., 2012b). Global 
metabolite profiling studies are revealing new discoveries linking cellular pathways to 
biological mechanism, shaping our understanding of cell biology, physiology and 
medicine (Panopoulos et al., 2012; Patti et al., 2012a; Tomita and Kami, 2012). 
In the present study we used serum samples of young and non-obese adolescents 
with HIAE, and age-, weight- and ethnicity-matched healthy controls. The results 
revealed that markers for the long-term health risks of HIAE, such as a type 2 diabetes 
and cardiovascular disease may be already detected early in adolescence with 
oxidative stress markers impacting HDL functionality through oxidation of 
apolipoprotein A1. We also demonstrate that a low-dose combination of PioFluMet 
during 18 months partially restores the levels of oxidative markers to the levels found 
in healthy girls. 
 
MATERIALS AND METHODS 
Study population. The study population consisted of 12 young, non-obese 
adolescents (age, 16.3±0.4 yr; BMI, 22.8±0.5 Kg/m
2
) diagnosed with HIAE and 14 age-, 
weight- and ethnicity-matched healthy controls. Adolescents with HIAE were recruited 
at the Endocrinology Unit of the Sant Joan de Déu-Barcelona Children’s Hospital, 
Barcelona (Spain), among those randomized into a clinical study comparing the effects 
of low-dose combination of PioFluMet with those of a frequently prescribed oral 
contraceptive [cyproteroneacetate 2 mg + 35 mcg ethynilestradiol for for 21 of 28 d, 
and placebo for 7 of 28 d] (Ibáñez L et al., 2013). The girls were chosen among those 
having enough serum sample left to allow for the required assessments. Controls were 
recruited among age-matched student mates with no clinical signs of androgen excess 
and normal menstrual cycles. 
Inclusion criteria were: 1) hyperinsulinemia, defined as fasting-insulinemia above 
15 U/ml and/or hyperinsulinemia on a standard 2-h oral glucose tolerance test, 
defined as peak insulin levels >150 U/mL and/or mean serum insulin >84 µU/mL; and 
2) the presence of both clinical and biochemical androgen excess, as defined by the 
following: hirsutism score above 8 (Ferriman-Gallwey), amenorrhea (no menses for 3 
months) or oligomenorrhea (menstrual cycles longer than 45 d); and high circulating 
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levels of and/or total testosterone (in the follicular phase (days 3–7) or after 2 months 
of amenorrhea. 
Exclusion criteria were: evidence of anemia, thyroid dysfunction, bleeding disorder, 
Cushing syndrome, or hyperprolactinemia; glucose intolerance; diabetes mellitus; late-
onset adrenal hyperplasia; abnormal electrolytes; abnormal screening of liver or 
kidney function; use of medication affecting gonadal or adrenal function, or 
carbohydrate or lipid metabolism. Pregnancy risk was a particular exclusion criterion 
that was not only taken into account when the study began, but was also maintained 
throughout the study in the PioFluMet subgroup. 
Ethics. This clinical study was registered as ISRCTN12871246 and conducted in Sant 
Joan de Déu University Hospital (Barcelona, Spain), after approval by the Institutional 
Review Board of Sant Joan de Déu University Hospital, and after written informed 
consent by each patient. 
Global metabolomics profiling. Untargeted metabolomic analyses on serum 
samples of HIAE and control girls were performed using two analytical platforms: 
1
H-
NMR and LC-ESI-QTOF; each serum sample was split into two aliquots and run in 
parallel using the two analytical platforms. For the NMR measurement 250 μL of serum 
were mixed with 250 μL of phosphate buffer (0.75 mM Na2HPO4 adjusted at pH 7.4, 
and 20% D2O to provide the field frequency lock). The final solution was transferred to 
a 5 mm NMR tube and kept refrigerated at 4ºC in the autosampler until the analysis. 
1
H-NMR spectra were recorded at 310 K on a Bruker Avance III 600 spectrometer 
operating at a proton frequency of 600.20 MHz using a 5 mm CPTCI triple resonance 
(
1
H, 
13
C, 
31
P). Three different 
1
H-NMR pulse experiments were performed for each 
sample: 1) Nuclear Overhauser Effect Spectroscopy (NOESY)-presaturation sequence to 
suppress the residual water peak; and 2) Carr-Purcell-Meiboom-Gill sequence (CPMG, 
spin-spin T2 relaxation filter) with a total time filter of 410 ms to attenuate the signals 
of serum macro-molecules to a residual level; 20 ppm spectral width and a total of 64 
transients collected into 64 k data points. 
The second aliquot was used for LC-MS analysis. 30 μL of serum sample was mixed 
with 120 μL of cold ACN/H2O (1:1) with 1% meta-phosphoric acid (MPA) and 0.1% 
formic acid (previously filtered). Samples were vortexed vigorously for 30 seconds and 
stored at –20ºC for 2 hours to enable protein precipitation. Subsequently, samples 
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were centrifuged 15 minutes at 4ºC and 15000 rpm and the supernetant was 
transferred to a LC-MS vial. Samples were injected in a UHPLC system (1290 Agilent) 
coupled to a quadrupole time of flight (QTOF) mass spectrometer (6550 Agilent 
Technologies) operated in positive electrospray ionization (ESI+) mode. Metabolites 
were separated using either C18-RP (ACQUITY UPLC HSS T3 1.8 μL, Waters) or HILIC 
(ACQUITY UPLC BEH 1.7 μL, Waters) chromatography at a flow rate of 0.4 mL/min. The 
solvent system in C18-RP was A= 0.1% formic in water, and B= 0.1% formic in 
acetonitrile. The linear gradient elution started at 100% A (time 0–3 min) and finished 
at 100% B (20–21 min). The solvent system in HILIC was A= 50mM NH4OcA in water, 
and B= ACN. The linear gradient elution started at 95% B (time 0–2 min) and finished at 
55% B (6 min). The injection volume was 2 μL. ESI conditions were gas temperature, 
225 °C; drying gas, 13 L min
–1
; nebulizer, 20 psig; fragmentor, 125 V; and skimmer, 65 
V. The instrument was set to acquire over the m/z range 80–1200 with an acquisition 
rate of 4 spectra/s. Quality control samples (QC) consisting of pooled serum samples of 
all patients were used. QC samples were injected before the first study sample and 
then periodically after five-study samples. Furthermore, real samples were randomized 
to reduce systematic error associated with instrumental drift. MS/MS was performed 
in targeted mode, and the instrument was set to acquire over the m/z range 50–1000, 
with a default iso width (the width half-maximum of the quadrupole mass bandpass 
used during MS/MS precursor isolation) of 4 m/z. The collision energy was fixed at 20 
V. 
Targeted metabolomics: Relevant metabolites were measured again using an 
UHPLC system (1290 Agilent) coupled to a triple quadrupole (QqQ) MS (6490 Agilent 
Technologies) operated in multiple reaction monitoring (MRM) and positive 
electrospray ionization (ESI+) mode.  MRM transitions were: methionine (150→ 56, 
61), methionine sulfoxide (166→ 56, 74), Taurine (126→ 41, 85), glutamate (148→56, 
84), cysteine-glycine (179→ 59, 116), glutathione (308→ 76, 162), glutathione oxidized 
(613→ 355, 484), glutamate-glutamate (277→ 84, 130), glutamate-cysteine (251→ 84, 
122), 5-oxoproline (130→ 56, 84). 
Characterization of lipoprotein classes:  
1
H NMR spectra were recorded at 310 K 
on a Bruker Avance III 600 spectrometer operating at a proton frequency of 600.20 
MHz (14.1 T). We used the double stimulated echo (DSTE) pulse program with bipolar 
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gradient pulses and a gradient pulse strength of 25% of the maximum strength of 53.5 
Gauss cm
-1
 in order to completely attenuate signals from low molecular weight 
metabolites. The relaxation delay was 2 s, the free induction decays (FIDs) were 
collected into 64K complex data points and 32 scans were acquired on each sample. 
The methyl signal was line-shape fitted using eight 1D Lorentzian functions using a 
modification of a previously reported protocol (Mallol et al., 2013). According to the 
NMR-derived lipoprotein sizes previously described, functions 2 to 8 were associated 
with 1 VLDL, 2 LDL, and 4 HDL lipoprotein subclasses, respectively. For simplification, 
functions 7 to 8 were grouped to obtain the small HDL subclass. 
Data analysis and statistical methods. The acquired CPMG NMR spectra were 
phased, baseline corrected and referenced to the chemical shift of the α-glucose 
anomeric proton doublet at 5.23 ppm. Pure compound references in BBioref AMIX 
(Bruker), HMDB and Chenomx databases were used for metabolite identification. After 
baseline correction, intensities of each 1H-NMR regions identified in the CPMG 1D-
NMR spectra were integrated for each sample entering the study using the AMIX 3.8 
software package (Bruker, GmBH). 
LC-MS (RP-C18 and HILIC ESI+ mode) data were processed using the XCMS software 
(Smith et al., 2006) (version 1.38.0) to detect and align features. A feature is defined as 
a molecular entity with a unique m/z and a specific retention time. XCMS analysis of 
these data provided a matrix containing the retention time, m/z value, and integrated 
peak area of each feature for every serum sample. The tab-separated text files 
containing LC-MS data were imported into R software where QC samples were used to 
filter analytical variation as previously reported (Vinaixa et al., 2012). Then univariate 
statistical analysis was performed using robust statistics (Yuen-Welch’s t-test). 
Differentially regulated metabolites (fold>1.5) that passed our statistical criteria (p-
value<0.01) were characterized by LC-qTOF MS/MS and identified using Metlin 
database or pure standards purchased on our lab.  
SDS-PAGE and trypsin digestion of apolipoprotein A1. Protein precipitation was 
carried out adding 10% of pure trichloroacetic acid (TCA) to 10 μL of serum. Samples 
were vortexed vigorously and incubated on ice for 1 hour. Samples were then 
centrifuged at 4ºC and 14.000 rpm for 15 minutes and the supernatants were 
discarded. 800 μL of cold acetone (-20ºC) were added to the pellet and proteins were 
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suspended and incubated overnight (-20ºC). Samples were centrifuged and the 
supernatant discarded again. This step was repeated and the pellet was air-dried. 
Pellet was resuspended with 100 μL of urea (7M), thiourea (2M) and CHAPS (4%) 
buffer. 10 μL of this solution were added to 30 μL of Laemmli Buffer (4x). 40 μL of such 
solution was applied to a home-made 12% acrylamide/bis-acrylamide SDS-PAGE gel. 
Proteins were Coomassie stained. The band of interest corresponding to Apo-A1 
(MW: 28,1 kDa) was manually excised from 1D SDS-PAGE gels, destained and washed 
with 25 mM AmBic for 15 min followed by a wash with acetonitrile for 15 min. These 
washes were twice repeated and samples were finally dehydrated with 100% 
acetonitrile and dried in a Speed-Vack concentrator. Apo-A1 was cysteine 
carbamidomethylated by placing the dried gel at 56 ºC for 1 h in a reducing solution 
containing 10 mM DTT and 50mM ammonium bicarbonate. Alkylation of the cysteines 
was achieved by incubation of the gel for 30 min in the dark with 55 mM 
iodoacetamide in 25 mM ammonium bicarbonate buffer. Gel pieces were alternately 
washed with 25 mM AmBic and 25 mM AmBic with acetonitrile, and finally dehydrated 
with 100% acetonitrile and dried under vacuum. Gel pieces were incubated with 12.5 
ng/µl sequencing grade trypsin (Roche Molecular Biochemicals) in 25 mM AmBic 
overnight at 37°C. After digestion, the supernatants were separated. Peptides were 
extracted from the gel pieces into 50% ACN, 0.1% trifluoroacetic acid. For each 
extraction, samples were incubated for 10 min in an orbital shaker. All extracts were 
pooled and the volume reduced using a vacuum concentrator. In order to obtain a 
suitable sample for mass spectrometry analysis the pellet was resuspended in 25μL of 
0.1% TFA/water, desalted and concentrated using C18 ZipTips (Millipore). Tryptic 
peptides were sequentially eluted with 5 μL of 70% acetonitrile with 0.1% TFA in 
water. 
MALDI-TOF MS analysis of Apo-A1. Samples were spotted on the MALDI plate 
following the dried-droplet method. Briefly, 1 μl of the reconstituted in-gel digest 
sample was spotted on a BigAnchorChip target plate (BrukerDaltonics), followed by 
1 μl of matrix (10 mg/ml α-cyano-4-hydroxycinnamic acid matrix (BrukerDaltonics) in 
50% ACN, 0.1% trifluoroacetic). Sample and matrix mixture was dried at room 
temperature. Mass spectra were obtained on an UltrafleXtreme (BrukerDaltonics, 
Bremen, Germany) matrix-assisted laser desorption ionization–tandem time of flight 
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(MALDI-TOF/TOF) mass spectrometer. Mass spectra were recorded in positive 
ionization reflectron mode in the mass range of 700–3500 Da. Operating conditions 
were as follows: ion source 1 = 25.00 kV, ion source 2 = 24.40 kV, lens 
voltage = 8.50 kV, reflector voltage = 26.45 kV, optimized pulsed ion extraction 
time = 130 ns, matrix suppression = 500 Da. 1500 single-shot spectra were 
accumulated by recording 50-shot spectra at 10 random positions using fixed laser 
attenuation. Mass spectra were externally calibrated using a standard peptide mixture 
(Bruker); calibration was considered good when a value below 1 ppm was obtained. 
Peptide mass fingerprinting of Apo-A1 and quantization of the ratio MetOx-
148/Met-148. ProteinScape software (Bruker) supported by the Mascot search engine 
(Matrix Science) was used with the following parameters: SWISS-PROT non-redundant 
database filtered by homo sapiens taxonomy, two missed cleavage permission, 50-ppm 
measurement tolerance.  
Carbamidomethylation of cysteines was set as a fixed modification and methionine 
oxidation was set as a variable modification. Positive identifications were accepted 
with a Mascot score higher than that corresponding to a P value of 0.05. The 
quantification of the ratio MetOx-148/Met-148 was performed using the intensity of 
the peptide K.LSPLGEEMS.D (Flex Analysis, Bruker).  
 
RESULTS 
Endocrine and metabolic alterations associated with HIAE in young, non-obese 
girls. 
Endocrine and metabolic parameters were compared between a group of 12 
young, non-obese girls with HIAE and 14 age-, weight- and ethnicity-matched healthy 
controls. Table 1 shows mean values and the standard error of the mean for each 
variable. As expected by definition, endocrine alterations in adolescent girls with HIAE 
relative to healthy controls included increased significant (p≤0.05) serum levels of 
insulin, testosterone, dehydroepiandrosterone sulfate (DHEAS) and leptin. On the 
other hand, metabolic values such as the fasting glucose to insulin ratio, total 
cholesterol were increased in HIAE girls and HDL-cholesterol was decreased in HIAE 
girls. Levels of superoxide dismutase (SOD), a key antioxidant enzyme protecting the 
cells, were also decreased in PCOS. Two-hour glucose levels on an oral glucose 
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tolerance test (oGTT), triglycerides and LDL-cholesterol levels did not show differences 
from healthy control adolescents.     
Thus, hyperinsulinemia with normal fasting glucose levels in HIAE girls may reflect 
insulin resistance, as suggested by the increased ratio of glucose to insulin. However, 
we could disclose no evidences of impaired glucose tolerance, hyperglycemia or 
hypertriglyceridemia at this early age. 
 
Table 1. Physiological and biochemical parameters.  
 CTR        PCOS p-value 
Age (yr) 17.2 ± 0.4 16.3 ± 0.4 0.15 
BW SDS  0.3 ± 0.1 -0.2 ± 0.4 0.58 
Wt (kg) 58.8 ± 1.8 58.2 ± 1.2 0.92 
Ht (cm) 163.9 ± 1.3 160.0 ± 1.5 0.06 
BMI (Kg/m
2
) 21.8 ± 0.6 22.8 ± 0.5 0.23 
BMI SDS 0.2 ± 0.2 0.5 ± 0.2 0.16 
WBC (cell/mm3) 7.3 ± 0.3 7.8 ± 0.5 0.26 
Neutrophils (x1000/mm3) 4.1 ± 0.3 4.4 ± 0.5 0.63 
Lymphocytes (x1000/mm3) 2.2 ± 0.1 2.5 ± 0.22 0.41 
N/L (ratio) 1.9 ± 0.2 2.0 ± 0.4 0.51 
AST (μL/L) 16.6 ± 0.7 16.8 ± 1.6 0.59 
ALT (μL/L) 13.6 ± 1.0 13.2 ± 1.1 0.83 
oGTT (mg/dL) 89.1 ± 1.5 85.4 ± 2.0 0.14 
Insulin (µU/mL) 3.5 ± 0.6 10.3 ± 1.6 0.01 
G/I ratio 32.8 ±3.6 11.2 ± 1.9 0.0004 
Total Cholesterol 143.9 ± 5.9 145.9 ± 6.8 0.75 
HDL-cholesterol 52.6 ± 2.3 51.9 ± 3.3 0.77 
LDL-cholesterol 80.5 ± 5.4 78.7 ± 4.5 0.88 
Triglycerides 53.4 ± 3.6 76.8 ± 16.5 0.57 
Testosterone (ng/dL) 32 ± 2.4 64.2 ± 10.2 0.05 
DHEAS (μg/dL) 222.1 ± 27.8 280.8 ± 31.5 0.03 
Leptin (ng/mL) 13.9 ± 2.3 20.9 ± 2.7 0.05 
usCRP (mg/L) 0.7 ± 0.2 1.1 ± 0.2 0.14 
SOD (U/mL) 6.1 ± 0.3 5.4 ± 0.2 0.03 
Data are represented as mean±standard error of the mean (SEM). P-values are calculated from 
a robust Yuen-Welch’s t-test. BW SDS: Birth weight standard desviation, Wt: weight, Ht: height, 
BMI: body mass index, BMI SDS: body mass index standard desviation, WBC: white blood cells, 
N/L: Neutrophils/Lymphocytes, AST: aspartate transaminase, ALT: alanine aminotransferase, 
oGTT: oral glucose tolerance test, G/I ratio: Glucose/insuline ratio, DHEAS: 
dehydroepiandrosterone sulfate, usCRP: ultrasensitive-C-Reactive Protein, SOD: superoxid 
dismutase. 
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Alteration of the VLDL, LDL and HDL serum profile in non-obese adolescents with 
HIAE  
Dyslipidemia is a characteristic lipid abnormality in PCOS and it is an important risk 
factor linked to metabolic syndrome, T2D and CVD. Here we studied the lipoprotein 
profile of adolescent girls with HIAE beyond standard measurement of cholesterol 
content of lipoproteins, by using an advanced lipoprotein analysis based on nuclear 
magnetic resonance (NMR) spectroscopy (Mallol et al., 2013). 
1
H-NMR allowed us to 
characterize the size and relative abundance of lipoprotein particles in serum. Briefly, 
depending on the size of the lipoprotein particle, the methyl moieties of the lipids in 
lipoproteins resonate at slightly different frequencies, the smaller particles resonating 
at lower frequencies (Figure 1a). Our NMR-derived lipoprotein subclasses were defined 
as VLDL, large LDL, small LDL, large HDL, medium HDL, and small HDL. 
Relative levels of VLDL, small LDL and large LDL were significantly increased in HIAE 
relative to control girls. In contrast, the relative abundance of large, medium and small 
HDL subclasses were decreased in HIAE, with the greatest decline though associated 
with large HDL (Figure 1b). Table 2 shows the differences in serum lipoproteins 
between adolescent girls with HIAE and healthy controls. Thus, the NMR-based 
characterization of lipoprotein subclasses revealed a dyslipidemic profile in girls with 
HIAE, which is similar to the one observed in the metabolic syndrome and its 
associated pathologies; T2D and CVD (Dokras, 2013).  
 
Figure 1. Lipoprotein profile measured by NMR spectroscopy. (A) Bipolar LED pulse sequence 
1
H NMR 
spectra of a HIAE serum showing the fitting of the methyl band using the seven Lorentzian functions 
derived from our previously described methodology (B) Row-wise normalized areas showed as 
mean±sem. VLDL: very low-density lipoprotein, lLDL: large low-density lipoprotein, sLDL: small low-
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density lipoprotein, lHDL: large high-density lipoprotein, mHDL: medium high-density lipoprotein, sHDL: 
small high-density lipoprotein 
 
Table 2. NMR lipoprotein profile in serum samples.  
 % variation p-value 
VLDL 50 0.012 
Large LDL 20 0.0264 
Small LDL 31 0.0245 
Large HDL -63 0.00001 
Medium HDL -52 0.0058 
Small HDL -20 0.02 
Percentage of variation of each lipoprotein subclass in HIAE with respect to control girls, and p-
values (Yuen-Welch’s t-test). 
 
 
Metabolomics reveals altered glutathione biosynthesis via the γ-glutamyl cycle, 
and elevated levels of methione sulfoxide in HIAE.   
The relative abundance of serum metabolites in girls with HIAE and healthy 
controls were compared using an untargeted metabolomic approach based on reverse 
phase (RP)-C18 and HILIC chromatography coupled to electrospray ionization 
quadrupole time-of-flight mass spectrometry (LC ESI-QTOF-MS) in positive ionization 
mode in combination with 
1
H-NMR metabolite profiling (Supplementary Table 1). Our 
MS-based platform enabled us to observe greater than 38.000 metabolite features 
defined as molecular entities with a unique mass/charge and retention time value, 
after the analytical variability had been corrected. Only the integrated areas of those 
metabolite features above 5,000 spectral counts in at least one of the two groups were 
considered for quantification (see the Methods section for further details). We next 
structurally identified metabolites based on accurate mass and MS/MS data that 
differed between HIAE and healthy controls. We identified 7 and 7 metabolites using 
RP-C18 and HILIC, respectively, that showed a greater than 50% of variation with a p-
value < 0.01 (Yuen-Welch’s t-test) (Supplementary Table 2). We found that levels of γ-
glutamyl dipeptides were higher in serum of adolescent girls with HIAE compared to 
healthy controls. γ-glutamyl dipeptides are involved in the γ-glutamyl cycle that 
transports amino acids into cells and plays a key role for the synthesis and degradation 
of glutathione, which is a key reducing agent that protects from oxidative damage. 
Furthermore, the NMR analysis revealed lower levels of glycine in serum samples of 
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HIAE girls. Glycine can be added to the C-terminal of γ-glutamylcysteine (Glu-Cys) via 
the enzyme glutathione synthetase to produce reduced glutathione. Finally, lower 
levels of methionine in serum samples of HIAE were associated with greater levels of 
methionine sulfoxide in these patients, indicating increased oxidation of this 
aminoacid. 
To confirm that the biosynthesis of glutathione via the γ-glutamyl cycle was really 
altered in girls with HIAE, we quantified reduced glutathione and the ratio of reduced 
to oxidized glutathione (GSH/GSSG) using triple-quadrupole mass spectrometry (QqQ 
MS) and multiple reaction monitoring (MRM). At the same time, we requantified most 
significant metabolites described in Supplementary Table 1 using pure standards 
(when commercially available), and quantified the additional γ-glutamyl dipeptide Glu-
Cys not detected by our untargeted metabolomic approach (Table 3).  
Table 3.Targeted metabolomics. 
 % variation p-value 
Methionine -344 0.00005 
Methionine Sulfoxide 40 0.0018 
5-oxoproline 39 0.005 
Taurine 28 0.015 
Glu-Cys 37 0.0002 
Glu-Glu 35 0.027 
Glutamate 33 0.004 
GSH 34 0.036 
GSH/GSSG 29 0.023 
Glu-Taurine* 73 0.0000003 
Glu-Gly* 98 0.00015 
Glycine -20 0.031 
Percentage of variation and p-values (Yuen-Welch’s t-test) of metabolites. Negative and 
positive values indicate lower and higher levels, respectively, in girls with HIAE relative to 
healthy controls. Glu: glutamate, cys: cysteine, GSH: glutathione, Gly: glycine, GSH/GSSG: 
glutathione/oxidated glutathione. *Glu-taurine and *Glu-Gly could not be quantified by LC-
QqQ in MRM mode due to the lack of pure standards and reported values are from LC-qTOF 
MS. Gly’s value is from NMR. 
 
Glutamyl dipeptides (Glu-Glu, Glu-Tau, Glu-Cys and Glu-Gly), amino acids 
(glutamate, 5-oxoproline and taurine), GSH and the GSH/GSSG ratio were significantly 
elevated in HIAE. Therefore, the targeted analysis validated our untargeted 
metabolomic results and proved the activation of the γ-glutamyl cycle in HIAE to 
synthesize reducing agents in the form of GSH (Figure 2). 
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Figure 2. Identified and quantified metabolites involved in the γ-glutamyl cycle. The scatter plots show 
the relative abundance (i.e., intensity) of individual metabolites in controls and HIAE samples and 
trimmed mean (control in red and HIAE in blue). 
 
Moreover, the trend that we observed between methionine and methionine 
sulfoxide (MetOx) was confirmed, that is, a drop in methione levels (Figure 3A) comes 
with a significant increase in MetOx (Figure 3B) in adolescent girls with HIAE.   
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Figure 3.Targeted analysis of methionine and methionine sulfoxide. The scatter plots show the relative 
abundance of methionine (A) and methionine sulfoxide (B) in controls and HIAE samples and trimmed 
mean (control in red and HIAE in blue).   
 
Methionine residues in proteins can be readily oxidized by reactive oxygen species 
to MetOx (Stadtman et al., 2003). In the context of our study, oxidation of methione 
residues in apolipoprotein A1 (Apo-A1) has been associated with impaired reverse 
cholesterol transport by HDL, and consequently, impaired maturation of HDL particles 
(Shao et al., 2008). This could partly explain the lower percentage of HDL particles, and 
more specifically, of large HDL particles in girls with HIAE relative to healthy controls 
(Figure 1). Since Apo-A1 is the major protein component of HDL and one of the most 
abundant proteins in human serum (Fisher et al., 2012), we hypothesized that girls 
with HIAE show greater oxidation of methionine residues in Apo-A1 relative to healthy 
girls. 
 
Quantitative analysis of the MetOx/Met ratio in Apo-A1 by MALDI-TOF MS 
To test the hypothesis that girls with HIAE suffer from increased oxidation of 
methionine residues in Apo-A1, we measured the ratio of MetOx/Met in Apo-A1 using 
SDS-PAGE and MALDI-TOF MS. In particular, we focused on a single methionine 
residue of Apo-A1, Met-148, the oxidation of which has been associated with loss of 
LCAT activity, a critical early step in reverse cholesterol transport (Sorci-Thomas and 
Thomas, 2002). 
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Briefly, we separated serum proteins of 10 non-obese adolescent girls with HIAE 
and 6 healthy controls using 1D SDS-PAGE, and the bands of interest corresponding to 
the molecular weight of Apo-A1 (28.1 kDa) were manually excised from the gel 
electrophoresis. After in-gel digestion with trypsin, peptides were recovered for 
MALDI-TOF MS analysis (see the Methods sections for details). Apo-A1 sequence 
coverage was 61% on average and MetOx-148/Met-148 was calculated from the ratio 
of peak intensity of peptides m/z 1047.51 (sequence K.LSPLGEEMR.D) and m/z 1411.67 
of Apo-A1. We recognize that MetOx could partly be generated during sample 
preparation and analysis as an artifact. However, since we measured the ratio MetOx-
148/Met-148 of Apo-A1 separately for each sample, this should not alter the relative 
differences between HIAE and control group. 
The ratio MetOx-148/Met-148 in Apo-A1 was significantly increased in girls with 
HIAE compared with healthy controls (Figure 4a). Furthermore, we found a positive 
and statistically significant correlation between the ratio MetOx-148/Met-148 in Apo-
A1 and free methionine sulfoxide in serum (Figure 4b). 
 
Figure 4. Apo-AI measurement. (A) Ratio of MetOx-148/Met-148 in apo-AI calculated from the intensity 
of the peptide K.LSPLGEEMR.D in Apo-A1. (B) Statistically significant correlation (p=6.95E-05 and r=0.8) 
between free methionine sulfoxide in serum and the oxidation state of apo-AI on the basis of the ratio 
of MetOx-148/Met-148 by MALDI-TOF MS. Control in red and HIAE in blue.    
 
 
Therefore, levels of methionine sulfoxide in serum are directly linked to the degree 
of oxidation of the Met-148 residue in Apo-A1, which could reflect turnover and 
proteolytic degradation of Apo-A1 proteins. 
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 Finally, there is also a negative correlation between the number of large (i.e., 
mature) HDL particles and methionine sulfoxide in serum (Figure 5), which reinforces 
our hypothesis that levels of methionine sulfoxide in serum reflect HDL oxidation, and 
indirectly, impaired maturation of HDL particles. 
 
Figure 5. Correlation results. Statistically significant negative correlation (p=1.13E-03 and r=-0.7) 
between free levels of methionine sulfoxide in serum and the percentage of large HDL particles. Control 
in red and HIAE in blue.   
 
Metabolic changes after 18 months of PioFluMet polytherapy in non-obese girls 
with HIAE  
Ibañez and colleagues demonstrated that a low-dose combination of PioFluMet 
proved to be more beneficial than oral contraceptives in regulating endocrine-
metabolic parameters, decreasing inflammation and visceral fat, and in improving 
markers of cardiovascular health (Ibanez et al., 2007).  
Here, we also measured the novel metabolic markers described above in girls with 
HIAE, after 18 months of PioFluMet polytherapy. Specifically, metabolites involved in 
the biosynthesis of GSH via the γ-glutamyl cycle, the size and relative abundance of 
lipoprotein particles, and the degree of oxidation of Apo-A1 by means of the MetOx-
148/Met-148 ratio were monitored using NMR and MS in the serum of 6 patients after 
18 months of PioFluMet treatment.   
The abundance of individual markers was scaled to unit variance and projected 
using an unsupervised principal component analysis (PCA) (Figure 6A). The scores plot 
reveals two clusters along PC1 (~47% of the variance) corresponding to adolescent girls 
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with HIAE on the one hand, and healthy controls and HIAE girls treated with PioFluMet 
on the other. This distribution indicates that the metabolic state of non-obese girls 
with HIAE after 18 months of PioFluMet treatment more closely resemble the state of 
healthy girls, suggesting an overall improvement of the metabolic conditions of HIAE. 
To interpret the pattern displayed in the scores plot, Figure 6B shows a loading bar 
plot of the PCA using each individual metabolic marker measured. The relative 
abundance of large HDL particles and levels of free methionine in serum are the two 
largest contributing variables to positive values in PC1. After the treatment with 
PioFluMet, the levels of methionine and large HDL particles recovered to the levels 
found in healthy girls (Figure 6c and 6d). Similarly, the levels of methionine sulfoxide 
and the oxidation of Apo-A1 in the Met-148 residue decreased after the treatment, 
reaching similar levels seen in healthy girls (Figure 6e and 6f).   
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Figure 6. Metabolic changes after 18 months of PioFluMet polytherapy. (A) PC1/PC2 scatter scores plot 
and (B) PC1 loading bar plot of PCA showing all the metabolites measured in HIAE patients after the 
treatment. (C) Relative intensity of free methionine in serum. (D) Percentage of large HDL particles in 
serum (E) Relative intensity of free methionine sulfoxide in serum. (F) Ratio of MetOx-148/Met-148 in 
apo-AI calculated from the intensity of the pepide K.LSPLGEEMR.D. 
 
DISCUSSION  
A better insight into hyperinsulinemic androgen excess (HIAE) in non-obese 
adolescents with a mild PCOS phenotype may contribute to the elucidation of early 
origins of PCOS and the causes of its association with an increased incidence of pre-
diabetic states (Apridonidze et al., 2005) and possibly cardiovascular events (Sukalich 
and Guzick, 2003). Ultimately, novel insights should sharpen the perspective of early 
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PCOS prevention (Ibanez et al., 2014). 
The PCOS phenotype has been associated with an imbalance between pro-oxidant 
and anti-oxidant mechanisms (Blair SA et al., 2013; Macut D et al., 2013), however, the 
underlying causes of this association remains unclear (Murri M et al., 2013). In our 
study the pro-oxidant events in adolescent girls with HIAE include low levels of the 
enzyme SOD, in accordance to previous studies (Seleem et al., 2014), increased 
oxidation of methionine residues in Apo-AI and accumulation of the oxidative marker 
methionine sulfoxide in HIAE serum. Interestingly, girls with HIAE appear to activate a 
compensatory and anti-oxidant mechanism that aims to regulate their redox status by 
synthesizing glutathione (GSH) through the γ-glutamyl cycle (Zhang et al., 2005). This is 
reflected in greater levels of the anti-oxidant GSH and the GSH/GSSG ratio in HIAE. 
Redox imbalances have been also described in atherosclerotic diseases (Stocker and 
Keaney, 2005), diabetes (Martitim et al., 2003; Sundaram et al., 1996) and metabolic 
syndrome (Roberts and Sindhu, 2009). 
Oxidative modifications are considered an initial step in lipoprotein conversion into 
more atherogenic particles (Kaysen and Eiserich, 2004; Shao et al., 2008), particularly 
in LDL particles (Jialal and Devaraj, 1996). In contrast, HDL cholesterol is generally 
associated with lower risk of cardiovascular disease (Valkenburg et al., 2008), 
metabolic syndrome and type 2 diabetes (von Eckardstein A and Widmann C, 2014). 
Concretely, HDL cholesterol is generally associated with atheroprotective properties, 
which include mediation of reverse cholesterol transport (Rosenson et al., 2013). The 
functional status of HDL is closely linked to its primary protein component, Apo-AI, an 
abundant apolipoprotein whose plasma concentrations are inversely correlated with 
the incidence of coronary artery disease (Borja et al., 2013). Notwithstanding, when 
Rajkhowa et al. measured the concentration of apo-AI in HDL particles in control and 
PCOS women, no change in the content of apoA-I was observed (Rajkhowa et al., 
1997).  
Alternatively, oxidation of methionine residues in apo-AI has been shown to impair 
reverse cholesterol transport by HDL (Shao et al., 2008). Specifically, the oxidation of 
Met-148 in apo-AI impairs apo-AI’s ability to activate lecithin cholesterol 
acyltransferase (LCAT) (Shao et al., 2008). LCAT is the enzyme responsible for 
transforming nascent HDL into spherical HDL particles containing a central 
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hydrophobic core of cholesteryl esters and an outer layer composed of apo-AI and 
phospholipids. Our NMR lipoprotein study shows lower percentage of large (i.e., 
mature) HDL particles in HIAE relative to control girls. This circumstance, together with 
the increased oxidation of Met-148 residues in apo-AI of HIAE girls suggests impaired 
HDL function and, consequently, reduced ability to form mature HDL particles. 
 It has recently been shown that hyperandrogenemia and glucose ingestion induce 
oxidative stress and that women with androgen excess fail to suppress the release of 
inflamation markers after glucose ingestion (González F et al., 2012; González F et al., 
2006; González et al., 2014). In the current period of caloric abundance and chronically 
positive energy balance for most adolescents (Corbett SJ et al., 2009), we postulate 
that hyperandrogenism in combination with excessive carbohydrate intake in a likely 
scenario of adipose tissue hypertrophy, may cause oxidative stress and oxidation of 
lipoprotein particles, resulting ultimately in impaired lipoprotein function and 
dyslipidemia. In our view, therefore, HIAE leads to alterations in lipoprotein 
metabolism, and both events precede other metabolic complications associated with 
the increased risk for metabolic syndrome (Anderson et al., 2014; Sharpless, 2003) and 
diabetes, including hypertriglyceridemia, impaired fasting glycemia and impaired 
glucose tolerance (Figure 7). 
 
Figure 7. Schematic representation of the underlying pathway by which HIAE is associated with 
long-term health risks, namely metabolic syndrome, diabetes and possibly, cardiovascular disease. 
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It is also tempting to speculate that the triad of methionine sulfoxide in serum, 
concentration of HDL subclasses (i.e., small, medium, large) and the ratio of 
methionine oxidation in apo-AI may represent novel biomarkers of pre-diabetes and 
metabolic syndrome. Further work is needed to study this combination of biomarkers 
in the general population.  
Finally, early treatment with low-dose PioFluMet proves again its efficacy on 
androgen excess and hyperinsulinemia (Ibáñez L et al., 2013), while improving the 
lipoprotein profile and most oxidative stress markers of non-obese adolescents with 
HIAE previously unknown. These observations extend further the benefits of therapies 
leading to a more physiological condition in adolescents with HIAE, questioning the 
rationale for applying symptom-directed therapies that might potentially impact on 
later co-morbidities (Beaber et al., 2014). 
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SUPPLEMENTARY MATERIAL 
 
 % variation p-value 
Lactate 25 0.0092 
Acetoacetate -20 0.1493 
Acetates -10 0.2945 
Alanine -3 0.6404 
Valine 11 0.0792 
Isoleucine+Valine -1 0.9184 
Leucine+Isoleucine -23 0.1711 
Glucose -9 0.0656 
Tyrosine -19 0.1009 
Hystidine -19 0.1951 
Glutamine -56 0.0004 
Free Glycerol -64 0.043 
Lysine -47 0.0530 
Glutamate 16 0.0717 
Creatine 3 0.4382 
Citrate -239 0.0187 
Glycine -20 0.031 
Supplementary Table 1. Metabolites identified by NMR. P-values were obtained from a Yuen-Welch’s t-
test. 
 
 
 % variation p-value UPLC Column 
Taurine 48 5.2E-03 HILIC 
Glutamate 94 4E-03 HILIC 
Methionine Sulfoxide 297 2.4E-05 HILIC 
Choline 57 1.9E-03 HILIC 
Methionine -99 1E-04 HILIC 
5-oxoproline 76 2.8E-03 HILIC 
Glutamine -31 1.5E-04 RP-C18 
Glu-Gly 98 1.5E-04 RP-C18 
Glu-Glu 82 3.1E-03 RP-C18 
Val-Glu 122 7.9E-04 RP-C18 
Glu-Taurine 250 3E-07 RP-C18 
PC (16:1) 667/428 3.7E-05 HILIC & RP-C18 
PC (10:2) 700 5E-04 RP-C18 
Supplementary Table 2. Metabolites identified by RP-C18 and HILIC that showed a greater than 50% of 
variation with a p-value < 0.01 (Yuen-Welch’s t-test) 
 
 
 
 
 
  
